ZedanMorgan Capital is led by experienced investment and growth-stage operations professionals. We have assembled an advisory board that includes distinguished pharmaceutical industry experts with deep experience in drug development, regulatory affairs, and commercialization. We are further supported by an extensive network of life science industry leaders and experts.
Amr F. Zedan
Founder, Managing Partner & Chairman
Amr F. Zedan has served as Chairman of The Zedan Group since 2000. He has transformed the enterprise from a small Saudi Arabia-based engineering consultancy into a preeminent international consortium of exemplary companies spanning the energy, infrastructure, real estate, aviation and digital transformation sectors. Zedan Group has partnered with many global firms operating in Saudi Arabia and has become a strategic partner for energy sector stakeholders and has a substantial role in all aspects of the Kingdom’s energy, infrastructure and economic diversification initiatives as outlined in Saudi Vision 2030.
Outside of his work with Zedan Group, Amr is an international investor and venture capitalist focusing on the energy, healthcare and technology sectors. Amr is Chairman of the Saudi Polo Federation, a governmental body that develops and promotes the sport in Saudi Arabia. Amr leverages polo as a cultural, business, and diplomatic tool to further enhance international bridges in line with Saudi Vision 2030. Amr also serves as patron and player for the Zedan Polo team and is the owner of USA-based Zedan Racing Stables.
Hoyt D. Morgan
Founder, Managing Partner & CEO
Hoyt brings more than two decades of successful business leadership: strategy, operations, private equity/investment, deal making, relationship building, data & analytics, management and team-building experience. He has a strong track record of value creation and value realization in his companies. Prior to ZedanMorgan, Hoyt was Vice President of Operations and on the Board of Directors at Accion Systems, a space technology company developing the next generation of in-space propulsion systems. Accion was majority acquired by Tracker Capital (the venture arm of Cerberus Capital). Hoyt was also CoFounder & CEO at Neuro Motor Innovations (a medical/neuroscience technology company acquired by Mindmaze SA) and CoFounder and CEO at Nito (a face tracking & animation technology company acquired by Verizon Media).
Hoyt graduated from Duke University with degrees in Economics and Management Sciences, and completed an International Business Program with American University in Washington, DC.
Principal, Investor Relations
Mutaz Maroun is an entrepreneur with a particular focus on emerging trends in healthcare. He is the founder of DocJo and Carers, two early-stage health-tech startups based in the Middle East and North Africa (MENA) region. Prior to founding these ventures, Mutaz had an accomplished career in the retail and industrial sectors, holding a range of senior roles across the Gulf Cooperation Council countries. He consistently identified growth opportunities, implemented strategies to exploit them, and integrated and motivated diverse business units across functions and geographies.
Mutaz holds an MA in International Relations from Syracuse University’s Maxwell School of Citizenship & Public Affairs with a concentration in Global Markets and the Middle East. Mutaz earned a BSc in Chemical Engineering with a minor in Entrepreneurship and Emerging Enterprises from Syracuse University. He has also completed the University of Oxford Blockchain Strategy Programme.
Robert R. Ruffolo, Jr.
Ph.D, D.Sc. (h.c.), D.Eng. (h.c.), F.C.P.P., F.ASPET.
Dr. Ruffolo is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. He is the retired President of Research and Development for Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). In that role, he managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to joining Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) where he was Senior Vice President and Director of Drug Discovery Research Worldwide with responsibility for approximately 1,700 scientists and an annual budget in excess of $1.2 billion. Prior to that, he was Senior Vice President of Biological Sciences, Worldwide and responsible for a staff of approximately 500 scientists and an annual budget in excess of $500 million. Before joining SmithKline Beecham, Dr. Ruffolo spent 6 years at Lilly Research Laboratories where he rose to the level of Chairman of the Cardiovascular Research Committee.
Dr. Ruffolo has authored approximately 500 full-length publications and has edited 15 books. In addition to being a member of the ZedanMorgan Advisory Board, Dr. Ruffolo is a consultant to the investment bank that sources opportunities for the Fund.
Gary L. Stiles, MD is a widely published doctor and pharmaceutical executive who has served on several corporate, academic and scientific advisory boards. He was most recently at Purdue Pharma as Head of Research and Development and Senior Vice-President, where he was responsible for all research including discovery, preclinical, formulations, analytics and toxicology, and all clinical development from IND submission through Phase 4 as well as medical support for marketed products. Prior to Purdue, Gary was Chief Medical Officer and Executive Vice President at Wyeth Pharmaceuticals where he was responsible for all clinical development from phase 1 through phase 4 and medical market support worldwide. Dr Stiles was also the global medical voice for Wyeth.
Prior to his corporate career, Gary had a distinguished career at Duke University. He was trained as a cardiologist and medical researcher at Duke and then joined the faculty where he ran his molecular biochemistry laboratory and became Chief of Cardiology and then Chief Medical Officer for the $2 billion Duke University Health System. Duke honored him with an endowed chair – the Ursula Geller Distinguished Professor of Cardiovascular Research – for his work on the molecular understanding of cellular signal transduction. During his tenure at Duke Gary served as a medical consultant to the Royal Family of Saudi Arabia and made several trips to the Kingdom to provide medical care.
Simon qualified as a barrister in England and Wales in 1981 and has since held senior executive roles at several major financial institutions including HSBC, JP Morgan, Citibank and Goldman Sachs. Simon has been living and working for extended periods in the Middle East, London, Hong Kong and Zurich where he was responsible for advising many leading Asian and Middle Eastern family-held companies and both single- and multi-family offices. After spending his early career living in the Gulf region (Bahrain and Qatar) he has spent most of the latter part of his career visiting the Kingdom of Saudi Arabia; Kuwait, Qatar and the UAE and advising single- and multi-family offices.